Studies into the optimal treatment of men with prostate cancer will be in the spotlight at the American Urological Association (AUA) 2014 Annual Scientific Meeting, which takes place from May 16 to 21 at the Orange County Convention Center in Orlando, Florida.

Among the controversial topics addressed will be whether active surveillance is a safe and effective alternative to immediate therapeutic interventions, the utility of prostate-specific antigen testing, and therapies for advanced prostate cancer, including castration-resistant disease.

The theme of this year's meeting is "Sharing Knowledge, Setting Standards." The first half of that slogan will be fulfilled by a wealth of clinical pearls, research presentations, symposia, forums, and workshops.

Setting Standards will be reflected, in part, by new and updated guidelines that will be presented in plenary sessions and accompanying courses.

New recommendations to be released include the Joint AUA/American Academy of Pediatrics Guideline on Evaluation and Treatment of Cryptorchidism, the AUA Guideline on Medical Management of Kidney Stones, and the AUA Guideline on Urotrauma.

In addition, the meeting will feature 2-hour courses during which the application of updated guidelines — for overactive bladder (non-neurogenic) in adults and castration-resistant prostate cancer — to clinical scenarios from urologic practice will be discussed.


One particularly interesting development that will be discussed at the meeting is a new indication for collagenase clostridium histolyticum (Xiaflex, Auxilium), according to Wayne Hellstrom, MD, professor of urology at Tulane University Medical Center in New Orleans, who serves on the editorial board for Medscape Urology.

"It's the first FDA-approved product that's come on the market for Peyronie's disease. We have no results yet, but it's an exciting thing that I think people will want to know about," he said in an interview with Medscape Medical News.

Dr. Hellstrom said he is also looking forward to hearing data on avanafil (Stendra,comarketed by VIVUS and Auxilium), a recently approved PDE-5 inhibitor that joins sildenafil (Viagra), tadalafil (Cialis), and vardenafil (Levitra and Staxyn) as a treatment for men with erectile dysfunction. The drug's presumed advantage is a rapid onset of action — as little as 15 minutes in some clinical trial participants — and it's cost relative to other agents, he said.

In addition, he's keen on hearing about human trials for botulinum toxin perineal injection (Botox, Allergan) to treat men with premature ejaculatory disorder.

Women's Health

Public perceptions of vaginal mesh surgery and removal will be the focus of several presentations at the meeting. They will involve studies of the way patients get information from the media, including the internet, and outcome and quality-of-life studies.

A session of the Society of Urodynamics, Female Pelvic Medicine and Urogenital Reconstruction will focus on urinary incontinence, voiding dysfunction after cancer therapy, and transvaginal repairs of vesico-vagingal fistulae.

Live and in 3-D!

Attendees will be able to view a live 3-dimensional video feed of a robotic prostatectomy performed by Ashutosh Tewari, MD, professor and chair of urology at Mount Sinai Hospital in New York City.

Other live surgery sessions planned include robotic and laparoscopic partial nephrectomy, concomitant female sling and vaginal repair for prolapse, and robotic sacrocolpopexy.

A Magical Time for Muggles

The AUA will hold its Grand Reception at Universal Studio's Islands of Adventure theme park, which includes the "Wizarding World of Harry Potter."

It promises to be a magical time, even for Muggles (the wizard-world term for us nonmagical folk).

Keep your browser pointed to Medscape Medical News for breaking news and more from AUA 2014.

Dr. Hellstrom reports financial relationships with American Medical Systems, Andromedical, Auxilium, Allergan, Coloplast, Cook Medical Inc., Endo Pharmaceuticals, Johnson & Johnson Pharmaceutical Research & Development, Lilly USA, the National Institutes of Health, Slate, Theralogix, and VIVUS.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.